{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T06:49:16Z","timestamp":1770965356846,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,1,29]],"date-time":"2019-01-29T00:00:00Z","timestamp":1548720000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004371","name":"Tampereen Yliopisto","doi-asserted-by":"publisher","award":["9V039"],"award-info":[{"award-number":["9V039"]}],"id":[{"id":"10.13039\/501100004371","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1038\/s41391-019-0129-2","type":"journal-article","created":{"date-parts":[[2019,1,29]],"date-time":"2019-01-29T15:18:43Z","timestamp":1548775123000},"page":"483-490","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Allopurinol and the risk of prostate cancer in a Finnish population-based cohort"],"prefix":"10.1038","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9584-8693","authenticated-orcid":false,"given":"Ville","family":"Kukko","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antti","family":"Kaipia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsi","family":"Talala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimmo","family":"Taari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teuvo L. J.","family":"Tammela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anssi","family":"Auvinen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teemu J.","family":"Murtola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,29]]},"reference":[{"key":"129_CR1","doi-asserted-by":"publisher","first-page":"3303","DOI":"10.1002\/art.39318","volume":"67","author":"LBE Kienhorst","year":"2015","unstructured":"Kienhorst LBE, van Lochem E, Kievit W, Dalbeth N, Merriman ME, Phipps-Green A, et al. Gout is a chronic inflammatory disease in which high levels of interleukin-8 (CXCL8), myeloid-related protein 8\/myeloid-related protein 14 complex, and an altered proteome are associated with diabetes mellitus and cardiovascular disease. Arthritis Rheumatol. 2015;67:3303\u201313.","journal-title":"Arthritis Rheumatol"},{"key":"129_CR2","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/nrrheum.2017.155","volume":"13","author":"AK So","year":"2017","unstructured":"So AK, Martinon F. Inflammation in gout: mechanisms and therapeutic targets. Nat Rev Rheumatol. 2017;13:639\u201347.","journal-title":"Nat Rev Rheumatol"},{"key":"129_CR3","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1093\/rheumatology\/kem235","volume":"46","author":"SJ Chang","year":"2007","unstructured":"Chang S-J, Tsai P-C, Chen C-J, Lai H-M, Ko Y-C. The polymorphism-863C\/A in tumour necrosis factor-alpha gene contributes an independent association to gout. Rheumatology. 2007;46:1662\u20136.","journal-title":"Rheumatology"},{"key":"129_CR4","first-page":"841","volume":"26","author":"PC Tsai","year":"2008","unstructured":"Tsai P-C, Chen C-J, Lai H-M, Chang S-J. Analysis of polymorphisms in the promoter region and protein levels of interleukin-6 gene among gout patients. Clin Exp Rheumatol. 2008;26:841\u20137.","journal-title":"Clin Exp Rheumatol"},{"key":"129_CR5","doi-asserted-by":"publisher","first-page":"150","DOI":"10.3109\/03009742.2012.726372","volume":"42","author":"S Liu","year":"2013","unstructured":"Liu S, Yin C, Chu N, Han L, Li C. IL-8 -251T\/A and IL-12B 1188A\/C polymorphisms are associated with gout in a Chinese male population. Scand J Rheumatol. 2013;42:150\u20138.","journal-title":"Scand J Rheumatol"},{"key":"129_CR6","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1158\/1055-9965.EPI-17-0503","volume":"26","author":"EA Platz","year":"2017","unstructured":"Platz EA, Kulac I, Barber JR, Drake CG, Joshu CE, Nelson WG, et al. A prospective study of chronic inflammation in benign prostate tissue and risk of prostate cancer: Linked PCPT and SELECT Cohorts. Cancer Epidemiol Biomark Prev. 2017;26:1549\u201357.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"129_CR7","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/978-3-319-95693-0_3","volume":"1095","author":"AK Tewari","year":"2018","unstructured":"Tewari AK, Stockert JA, Yadav SS, Yadav KK, Khan I. Inflammation and prostate cancer. Adv Exp Med Biol. 2018;1095:41\u201365.","journal-title":"Adv Exp Med Biol"},{"key":"129_CR8","first-page":"680853","volume":"2015","author":"W Wang","year":"2015","unstructured":"Wang W, Xu D, Wang B, Yan S, Wang X, Yin Y, et al. Increased risk of cancer in relation to gout: a review of three prospective cohort studies with 50,358 subjects. Mediat Inflamm. 2015;2015:680853.","journal-title":"Mediat Inflamm"},{"key":"129_CR9","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3109\/03009742.2013.878387","volume":"43","author":"CJ Chen","year":"2014","unstructured":"Chen C-J, Yen J-H, Chang S-J. Gout patients have an increased risk of developing most cancers, especially urological cancers. Scand J Rheumatol. 2014;43:385\u201390.","journal-title":"Scand J Rheumatol"},{"key":"129_CR10","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.jbspin.2011.09.011","volume":"79","author":"CF Kuo","year":"2012","unstructured":"Kuo C-F, Luo S-F, See L-C, Chou I-J, Fang Y-F, Yu K-H. Increased risk of cancer among gout patients: a nationwide population study. Jt Bone Spine. 2012;79:375\u20138.","journal-title":"Jt Bone Spine"},{"key":"129_CR11","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1097\/CEJ.0b013e328313631a","volume":"18","author":"P Boffetta","year":"2009","unstructured":"Boffetta P, Nordenvall C, Nyr\u00e9n O, Ye W. A prospective study of gout and cancer. Eur J Cancer Prev. 2009;18:127\u201332.","journal-title":"Eur J Cancer Prev"},{"key":"129_CR12","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s11010-016-2671-8","volume":"414","author":"F Sangkop","year":"2016","unstructured":"Sangkop F, Singh G, Rodrigues E, Gold E, Bahn A. Uric acid: a modulator of prostate cells and activin sensitivity. Mol Cell Biochem. 2016;414:187\u201399.","journal-title":"Mol Cell Biochem"},{"key":"129_CR13","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1177\/0960327109105406","volume":"28","author":"GD Castro","year":"2009","unstructured":"Castro GD, Costantini MH, Castro JA. Rat ventral prostate xanthine oxidase-mediated metabolism of acetaldehyde to acetyl radical. Hum Exp Toxicol. 2009;28:203\u20138.","journal-title":"Hum Exp Toxicol"},{"key":"129_CR14","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1158\/1541-7786.MCR-08-0012","volume":"6","author":"T Yasuda","year":"2008","unstructured":"Yasuda T, Yoshida T, Goda AE, Horinaka M, Yano K, Shiraishi T, et al. Anti-gout agent allopurinol exerts cytotoxicity to human hormone-refractory prostate cancer cells in combination with tumor necrosis factor-related apoptosis-inducing ligand. Mol Cancer Res. 2008;6:1852\u201360.","journal-title":"Mol Cancer Res"},{"key":"129_CR15","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/pcan.2017.14","volume":"20","author":"HJ Shih","year":"2017","unstructured":"Shih H-J, Kao M-C, Tsai P-S, Fan Y-C, Huang C-J. Long-term allopurinol use decreases the risk of prostate cancer in patients with gout: a population-based study. Prostate Cancer Prostatic Dis. 2017;20:328\u201333.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"3","key":"129_CR16","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/s41391-017-0031-8","volume":"21","author":"Ville Kukko","year":"2017","unstructured":"Kukko V, Kaipia A, Talala K, Taari K, Tammela TLJ, Auvinen A, et al. Allopurinol and risk of benign prostatic hyperplasia in a Finnish population-based cohort. Prostate Cancer Prostatic Dis. 2018;21:373\u20138.","journal-title":"Prostate Cancer and Prostatic Diseases"},{"key":"129_CR17","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1093\/jnci\/djt038","volume":"105","author":"TP Kilpel\u00e4inen","year":"2013","unstructured":"Kilpel\u00e4inen TP, Tammela TL, Malila N, Hakama M, Santti H, M\u00e4\u00e4tt\u00e4nen L, et al. Prostate cancer mortality in the Finnish randomized screening trial. J Natl Cancer Inst. 2013;105:719\u201325.","journal-title":"J Natl Cancer Inst"},{"key":"129_CR18","first-page":"267","volume":"50","author":"S Sarre","year":"2016","unstructured":"Sarre S, M\u00e4\u00e4tt\u00e4nen L, Tammela TLJ, Auvinen A, Murtola TJ. Postscreening follow-up of the Finnish Prostate Cancer Screening Trial on putative prostate cancer risk factors: vitamin and mineral use, male pattern baldness, pubertal development and non-steroidal anti-inflammatory drug use. Scand. J Urol. 2016;50:267\u201373.","journal-title":"J Urol"},{"key":"129_CR19","unstructured":"Rates of reimbursement for medicines.\n                     https:\/\/www.kela.fi\/web\/en\/reimbursements-for-medicine-expences-amount\n                    \n                  . Accessed 30 July 2018."},{"key":"129_CR20","unstructured":"WHOCC\u2014ATC\/DDD Index. \n                    https:\/\/www.whocc.no\/atc_ddd_index\/\n                    \n                  . Accessed 30 July 2018."},{"key":"129_CR21","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.eururo.2007.04.069","volume":"52","author":"WC Buschemeyer","year":"2007","unstructured":"Buschemeyer WC, Freedland SJ. Obesity and prostate cancer: epidemiology and clinical implications. Eur Urol. 2007;52:331\u201343.","journal-title":"Eur Urol"},{"key":"129_CR22","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/sj.bjc.6605188","volume":"101","author":"TJ Murtola","year":"2009","unstructured":"Murtola TJ, Tammela TLJ, M\u00e4\u00e4tt\u00e4nen L, Ala-Opas M, Stenman UH, Auvinen A. Prostate cancer incidence among finasteride and alpha-blocker users in the Finnish Prostate Cancer Screening Trial. Br J Cancer. 2009;101:843\u20138.","journal-title":"Br J Cancer"},{"issue":"6","key":"129_CR23","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.euf.2017.03.005","volume":"4","author":"Teemu Johannes Murtola","year":"2018","unstructured":"Murtola TJ, Vettenranta AM, Talala K, Taari K, Stenman U-H, Tammela TLJ, et al. Outcomes of prostate-specific antigen-based prostate cancer screening among men using nonsteroidal anti-inflammatory drugs. Eur Urol Focus. 2018;4:851\u20137.","journal-title":"European Urology Focus"},{"key":"129_CR24","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1097\/BOR.0000000000000028","volume":"26","author":"T Bardin","year":"2014","unstructured":"Bardin T, Richette P. Definition of hyperuricemia and gouty conditions. Curr Opin Rheumatol. 2014;26:186\u201391.","journal-title":"Curr Opin Rheumatol"},{"key":"129_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-016-0732-1","volume":"14","author":"JA Singh","year":"2016","unstructured":"Singh JA. Gout: will the \u201cKing of Diseases\u201d be the first rheumatic disease to be cured? BMC Med. 2016;14:180.","journal-title":"BMC Med"},{"key":"129_CR26","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s11926-017-0688-y","volume":"19","author":"GE Thottam","year":"2017","unstructured":"Thottam GE, Krasnokutsky S, Pillinger MH. Gout and metabolic syndrome: a tangled web. Curr Rheumatol Rep. 2017;19:60.","journal-title":"Curr Rheumatol Rep"},{"key":"129_CR27","first-page":"19","volume":"11","author":"T Klaukka","year":"2001","unstructured":"Klaukka T. The Finnish database on drug utilisation. Nor Epidemiol. 2001;11:19\u201322 19.","journal-title":"Nor Epidemiol"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41391-019-0129-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41391-019-0129-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41391-019-0129-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:33:53Z","timestamp":1684618433000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-019-0129-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,29]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["129"],"URL":"https:\/\/doi.org\/10.1038\/s41391-019-0129-2","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,29]]},"assertion":[{"value":"12 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"TLJT: consultant fees from Amgen, Astellas, Bayer, Ferring and Roche. TJM: consultant fees from Astellas and Janssen Cilag. Lecture fees from Astellas, GSK and Janssen Cilag. KT: Research funding from Medivation\/Astellas\/Pfizer, travel support from Astellas. The remaining authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}